Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
… ProQR Announces Results for the Second Quarter of 2016 … (NACFC)", said Daniel de Boer, Chief Executive Officer of ProQR. “For QR-110 for patients with LCA10, we presented … in this study include sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
… ProQR Announces Results for the First Quarter of 2016 LEIDEN, … pipeline", said Daniel de Boer, Chief Executive Officer of ProQR. “This quarter we organized an inaugural R&D Day where we, along with key opinion leaders presented …
… ProQR Announces Participation in Upcoming Kempen Life … & CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … 2021 Thematic Virtual Series on April 28, 2021. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Announces Results for the Third Quarter of 2016 LEIDEN, the Netherlands, Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel de Boer, Chief Executive Officer of ProQR “I’m proud of the team that has designed and executed …
… ProQR to Present at Three Scientific Conferences in April … and CAMBRIDGE, Mass., April 22, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … K. Koenekoop, MD, PhD, principle investigator of the ProQR Phase 1/2 STELLAR clinical trial of QR-421a and …
… ProQR to Present at the JMP Life Sciences Conference LEIDEN, the Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … am ET, Gerard Platenburg, Chief Innovation Officer of ProQR, will participate in an analyst led fireside chat …